The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M09 | Other drugs for disorders of the musculo-skeletal system | |
| 3 | M09A | Other drugs for disorders of the musculo-skeletal system | |
| 4 | M09AX | Other drugs for disorders of the musculo-skeletal system | |
| 5 | M09AX10 |
| Active Ingredient | Description | |
|---|---|---|
| Risdiplam |
Risdiplam is a survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier designed to treat SMA caused by mutations of the SMN1 gene in chromosome 5q that lead to SMN protein deficiency. Functional SMN protein deficiency is directly linked to the SMA pathophysiology which includes progressive loss of motor neurons and muscle weakness. Risdiplam treats SMA by increasing and sustaining functional SMN protein levels. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EVRYSDI Oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| EVRYSDI Powder for oral solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
